DAPLIMEDA-10
DAPLIMEDA-10 is a pharmaceutical tablet formulation containing Dapagliflozin 10 mg as its active pharmaceutical ingredient. The product is listed in the Suprimeda portfolio under the Anti-Diabetics category and is formulated as an oral tablet dosage form. Dapagliflozin belongs to the sodium-glucose cotransporter 2 (SGLT2) inhibitor class of pharmaceutical agents. Official pharmaceutical references identify dapagliflozin tablets as oral formulations available in 5 mg and 10 mg strengths.
For B2B pharmaceutical identification, relevant product descriptors include Dapagliflozin 10 mg tablets, Dapagliflozin tablets, SGLT2 inhibitor tablets, antidiabetic tablets and Dapagliflozin 10 mg formulation. The product pack shown features a blister-pack presentation, with the carton clearly specifying 10 × 10 tablets. The product information and dosage-form terminology are aligned with established pharmaceutical references for dapagliflozin tablets.
Everything You, Need to Know
DAPLIMEDA-10 is presented in a blister-pack format, and the product carton shown specifies a packaging size of 10 × 10 tablets.
DAPLIMEDA-10 is an oral tablet formulation containing 10 mg of Dapagliflozin. Official pharmaceutical references also identify Dapagliflozin 10 mg as an oral tablet strength.
DAPLIMEDA-10 contains Dapagliflozin 10 mg as its active pharmaceutical ingredient and is formulated as a tablet. This composition is confirmed in the Suprimeda product document.